AbbVie Inc. (ABBV) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for ABBV is $275.95 — 7.6% above the latest price of $256.48.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for AbbVie is driven by the continued robust growth and market dominance of its immunology powerhouses, Skyrizi and Rinvoq, with combined sales anticipated to exceed $30 billion by 2027. The neuroscience franchise, with drugs like Vyalev, Botox Therapeutic, and Ubrelvy, is also expected to contribute significantly to revenue diversification and growth. Strategic acquisitions in oncology, such as ImmunoGen and Cerevel, along with pipeline development, are anticipated to mitigate late-decade pipeline concerns and potentially yield new blockbuster revenue streams. Furthermore, strong operating leverage and an improving margin profile are expected to support accelerating dividend increases and increased business development activity.
Bear Case
The bear case for AbbVie primarily centers on valuation risk, as the stock is trading at a high earnings multiple, suggesting that substantial future growth might already be priced in. Any regulatory delays or disappointing clinical trial data for pipeline assets could trigger a significant negative market reaction. While Skyrizi and Rinvoq are strong growth drivers, future immunology competition and their eventual loss of exclusivity later this decade pose long-term risks. Continued residual erosion from Humira biosimilars could also weigh on reported growth. Additionally, concerns exist regarding the breadth and differentiation of AbbVie's obesity pipeline, which may necessitate further timely acquisitions to remain competitive.
Model-assessed risk level: Low
Key Catalysts to Watch
Continued market share gains and label expansions for Skyrizi and Rinvoq, including new indications like Skyrizi's subcutaneous induction for Crohn's disease.
Strong performance and pipeline advancements within the Neuroscience franchise, particularly Vyalev achieving blockbuster status.
Successful integration of recent strategic acquisitions in oncology and the progression of the oncology pipeline.
Technical Backdrop
RSI-14
52.0
50-Day MA
$249.78
200-Day MA
$229.98
From 52-Wk High
-3.6%
Full momentum breakdown: Is ABBV overbought or oversold?
Model Notes
AbbVie Inc. is an American pharmaceutical company, a spin-off from Abbott Laboratories, that focuses on discovering and delivering innovative medicines across several key therapeutic areas, including immunology, oncology, neuroscience, and aesthetics. The company has successfully navigated the patent expiration of its blockbuster drug Humira through the strong performance of its next-generation immunology treatments, Skyrizi and Rinvoq. AbbVie consistently reports robust financial results, exceeding analyst expectations for both earnings and revenue, driven by strong product demand and strategic acquisitions. Analyst sentiment is predominantly positive, with a consensus 'Buy' rating and rising price targets, reflecting confidence in the company's growth drivers and pipeline.
AbbVie's stock is currently in a rising trend channel in the medium term, indicating sustained investor interest. The stock has been moving within a rectangular formation with support around $243 and resistance at $267. As of August 31, 2026, the price closed at $255.96, above key support levels. Technical analysis signals are mixed but lean slightly bullish, with 15 bullish indicators against 11 bearish signals. Several moving averages, including the 20-day, 50-day, and 200-day exponential and simple moving averages, suggest a 'Buy' signal, while shorter-term 8-day moving averages indicate a 'Sell' signal.
Current Street Context
August 28, 2026The AI price target for AbbVie is $275.95. Analyst sentiment appears to be somewhat mixed, with recent reports indicating a price target raise to $300 from $295 by Wells Fargo and an upgrade to Outperform from Peer Perform by Wolfe Research. However, the company's Q2 2026 EPS of $3.65 missed some analyst estimates. AbbVie's next earnings report is estimated for October 23, 2026, or October 30, 2026, for Q3 2026, with a consensus EPS forecast of $3.86. Key events include the ongoing performance of its immunology and neuroscience portfolios, and the integration of acquisitions like Apogee Therapeutics, which could impact future earnings. Price targets are estimates and should not be considered guarantees.
Frequently Asked Questions
What is the price target for ABBV?
How is this forecast generated?
How accurate are stock price predictions?
Will ABBV stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews ABBV’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on ABBV
AbbVie Inc. Overview
Price, chart, analysis & financials
ABBV: Overbought or Oversold?
Updated daily
ABBV: Why Is It Moving?
Updated daily
ABBV: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers